Shopping Cart
- Remove All
- Your shopping cart is currently empty
Adebrelimab (SHR-1316) is a humanized monoclonal antibody targeting PD-L1 with antitumor activity for the study of solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $645 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,530 | In Stock | |
50 mg | $1,980 | In Stock | |
100 mg | $2,790 | In Stock |
Description | Adebrelimab (SHR-1316) is a humanized monoclonal antibody targeting PD-L1 with antitumor activity for the study of solid tumors. |
In vitro | Adebrelimab (0.06-1 mg/mL; treated for 48 hours) significantly inhibited the proliferation, migration, and invasion of SK-BR-3 and AU565 cells. [1] Adebrelimab (0.1-1 mg/mL; 48 hrs) decreased the expression of PD-L1, p-PI3K, and p-AKT, and increased the expression of FOXO1. [1] |
In vivo | Adebrelimab (200 μg; administered 3 times per week for 21 days) showed significant inhibition of tumor growth. [1] |
Alias | SHR-1316, SHR1316, HTI-1316, HTI1316, HTI-1088, HTI1088 |
Cas No. | 2247114-85-6 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.